Breaking Down China Resources Boya Bio-pharmaceutical Group Co., Ltd. Financial Health: Key Insights for Investors

China Resources Boya's recent filings reveal a mix of rebounds and warning signs that investors should parse closely: Q3 2025 revenue climbed to ¥466.15 million (+33.43% YoY) and year-to-date revenue sits at ¥1.47 billion (+18.38% YoY) while H1 revenue reached ¥1.008 billion (+12.51% YoY) alongside a 320.39-ton plasma collection (+7.2% YoY); profitability shows Q3 net profit of ¥117.62 million (+21.59% YoY) but YTD net profit of ¥342.96 million (-16.90% YoY) with Q3 EPS at ¥0.23 (+21.05% YoY) and YTD EPS of ¥0.68 (-17.07% YoY) after inventory write-downs and asset amortization from the Green Cross acquisition; the balance sheet as of Sept 30, 2025 reports total assets of ¥8.73 billion, liabilities of ¥1.05 billion and shareholders' equity of ¥7.67 billion (debt-to-equity ≈0.14) while liquidity flags include cash and equivalents of ¥761.75 million (-41.40% since Dec 31, 2024) and operating cash flow of ¥26.11 million in Q3 (-90.05% YoY), even as management plans a cash dividend of ¥1.5 per 10 shares and China Resources Medicine raised its stake to 41.79%; market metrics (Dec 12, 2025) show a stock price of ¥22.92, market cap ¥11.56 billion, P/E 35.25 (forward 20.10) and a ¥0.30 dividend (yield 1.31%), set against material risks from the Green Cross integration, reimbursement pressures, and pending plasma station approvals - and notable growth catalysts like approval for subcutaneous immunoglobulin trials, the May 2025 launch of 10% immunoglobulin, international registrations, and a Chinese blood-products market projected from ~¥60 billion in 2024 toward ¥100 billion by 2030; read on to unpack what these figures mean for investment decisions.

China Resources Boya Bio-pharmaceutical Group Co., Ltd. (300294.SZ) - Revenue Analysis

• Q3 2025 revenue: ¥466.15 million (+33.43% YoY)
• 2025 year-to-date revenue: ¥1.47 billion (+18.38% YoY)
• H1 2025 revenue: ¥1.008 billion (+12.51% YoY vs H1 2024)
• 2024 full-year revenue: ¥1.73 billion (-34.58% vs 2023) - decline driven by divestitures and asset impairments
• Plasma collection volume (2025 YTD): 320.39 tons (+7.2% YoY)

• Volume driver: plasma collection up 7.2% YoY to 320.39 tons, supporting revenue recovery in plasma-derived products.
• Structural note: 2024 disposals/impairments caused a lower revenue base, making 2025 YoY growth rates higher versus the depressed 2024 figures.
• Investor consideration: differentiate underlying organic growth (volume-based) from one-off effects tied to asset transactions and impairments.

China Resources Boya Bio-pharmaceutical Group Co., Ltd. (300294.SZ) - Profitability Metrics

• Q3 2025 net profit: ¥117.62 million (up 21.59% YoY), supported by improved quarterly operating performance and margin recovery.
• YTD 2025 net profit: ¥342.96 million (down 16.90% YoY), reflecting cumulative impacts of one-off and non-cash charges.
• H1 2025 net profit attributable to shareholders: ¥225 million, forming a material portion of YTD results.
• Q3 basic and diluted EPS: ¥0.23 (up 21.05% YoY); YTD EPS: ¥0.68 (down 17.07% YoY).
• Management cites inventory write-downs and accelerated asset amortization tied to the Green Cross acquisition as key drivers of the YTD decline in profitability.

China Resources Boya Bio-pharmaceutical Group Co., Ltd. (300294.SZ) - Debt vs. Equity Structure

• Low leverage: A debt-to-equity ratio of ~0.14 signals a conservative capital structure with liabilities representing a small portion of financing relative to equity.
• Strong equity base: Shareholders' equity of ¥7.67 billion (up 2.45% YTD) supports balance-sheet resilience and capacity for R&D or M&A without heavy reliance on debt.
• Liquidity and solvency considerations: Total liabilities of ¥1.05 billion against assets of ¥8.73 billion imply robust solvency metrics and ample buffer for operational volatility.

• Strategic endorsement: The completion of the share increase and China Resources Medicine Holdings' incremental acquisition (6,050,900 shares) raising its stake to 41.79% is a strong signaling event of sponsor confidence.
• Governance implications: Increased strategic shareholding concentrates control and may align long-term strategy, but investors should monitor related-party arrangements and board composition.

• Investor takeaways:
  • Capital risk is limited by low leverage; downside from balance-sheet stress is reduced.
  • Equity growth (+2.45%) is modest but positive-watch for continuation in next reporting periods.
  • Major shareholder backing can catalyze strategic initiatives but may also reduce free-float and liquidity.

China Resources Boya Bio-pharmaceutical Group Co., Ltd. (300294.SZ) - Liquidity and Solvency

• Cash and cash equivalents (as of 2025-09-30): ¥761.75 million (a 41.40% decrease vs. 2024-12-31).
• Operating cash flow (Q3 2025): ¥26.11 million, down 90.05% year-over-year.
• Cash dividend proposal: ¥1.5 per 10 shares (demonstrates ongoing commitment to solvency and shareholder returns).
• Management cites declines in cash reserves due to: investments in wealth management products, project payments, and dividend distributions.
• Company is actively applying for new plasma collection stations to bolster operating liquidity and working capital generation.

• Key investor considerations:
• Near-term liquidity shows stress given sharp cash and operating-CFO declines; however, the dividend plan and operational expansion (plasma stations) indicate management confidence in solvency and future cash-generation recovery.

China Resources Boya Bio-pharmaceutical Group Co., Ltd. (300294.SZ) - Valuation Analysis

• Stock price: ¥22.92 (12-Dec-2025)
• Market capitalization: ¥11.56 billion
• Trailing P/E: 35.25
• Forward P/E: 20.10
• Declared dividend: ¥0.30 per share (yield 1.31%)
• 1-year price change: -26.47%

• P/E interpretation: A trailing P/E of 35.25 suggests the stock is priced for higher growth relative to lower-P/E peers, while the forward P/E of 20.10 implies expected earnings improvement or normalization.
• Dividend context: The ¥0.30 per-share payout (1.31% yield) signals management's willingness to return cash, though yield remains modest versus high-yield dividend peers.
• Price action: A 26.47% decline over the past year may reflect near-term earnings pressure, sector rotation, or idiosyncratic company developments-contributing to a lower market cap despite valuation multiples.

China Resources Boya Bio-pharmaceutical Group Co., Ltd. (300294.SZ) - Risk Factors

• Acquisition-related impairments: the Green Cross acquisition has generated one-time and recurring charges, including inventory write-downs and accelerated amortization of acquired intangible assets, which compress margins and earnings quality in the near term.
• Market & reimbursement headwinds: pricing pressure and an uncertain reimbursement environment for plasma-derived products continue to affect revenue realization and extend receivable collection cycles.
• Liquidity pressures: a material decline in cash reserves accompanied by weakening operating cash flow points to potential short-term liquidity constraints, increasing reliance on non-operational funding and cash management strategies.
• Regulatory uncertainty on plasma capacity expansion: the company is actively applying for additional plasma collection stations, but approvals are uncertain and timing remains a key execution risk.
• Use of cash and portfolio positioning: recent reductions in cash balances are attributable to (a) investments in wealth-management products, (b) payments on ongoing projects (capex and integration), and (c) shareholder distributions; these choices influence available liquid buffers.
• Dividend continuation vs. solvency signal: the board's proposal to distribute a cash dividend of ¥1.5 per 10 shares signals confidence in solvency and capital return discipline, but also reduces retained liquidity that could otherwise support integration and working-capital needs.

• Key metrics and operational indicators to monitor: receivables days (DSO), inventory turns (post-acquisition), operating cash flow trend (quarterly YoY), available cash & cash equivalents, short-term borrowings, and regulatory approvals for plasma station applications.
• Red flags for investors: sustained negative operating cash flow, repeated inventory impairments, growing receivables without collection improvement, and delays/failures in obtaining plasma-station permits.

China Resources Boya Bio-pharmaceutical Group Co., Ltd. (300294.SZ) - Growth Opportunities

• Core focus: deepen investment and operational emphasis on blood product lines (immunoglobulins, factor VIII, PCC) and increase comprehensive utilization of plasma-derived raw material.
• Marketing and channel evolution: dynamic adjustment toward chronic disease management platforms and more integrated patient-care solutions, supporting higher patient retention and repeat dosing for blood products.
• Product innovation and regulatory progress: approval for clinical trials of subcutaneous immunoglobulin and market approval of a 10% immunoglobulin product in May 2025, with expectations of staggered partial approvals during the year.
• International expansion: drug registration certificates in the Dominican Republic and GMP certification in Turkey for select products, opening export and contract-manufacturing opportunities.

• Market opportunity: with the blood-products segment forecast to grow from ~¥60bn (2024) to ~¥100bn (2030), incremental annualized demand supports sizable volume and revenue upside for scaled plasma processors and manufacturers.
• Product mix leverage: higher-margin specialty proteins (e.g., 10% IG, factor VIII) and switchable administration routes (IV → subcutaneous) can raise ASPs (average selling prices) and improve margins per vial/dose.
• Commercial execution: chronic disease management platforms are expected to increase lifetime patient value and adherence - positive for recurring-consumption products like immunoglobulins and clotting factors.
• International revenue stream: registrations and GMP approvals create new addressable markets and de-risk concentration on domestic channels.